These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22410678)

  • 1. Prostate cancer: modeling the outcomes of prostate cancer screening.
    Loeb S; Carlsson S; Braithwaite RS
    Nat Rev Urol; 2012 Mar; 9(4):183-5. PubMed ID: 22410678
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?
    Sugimoto M; Kakehi Y
    Asian J Androl; 2012 Jul; 14(4):522-4. PubMed ID: 22751444
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: Prudent practice optimizes screening outcomes.
    Auvinen A
    Nat Rev Urol; 2016 Jul; 13(7):376-7. PubMed ID: 27215425
    [No Abstract]   [Full Text] [Related]  

  • 5. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 6. The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
    Hamdy FC
    BJU Int; 2016 Dec; 118(6):843. PubMed ID: 27870364
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostate cancer with PSA testing: current status and future directions.
    Croswell JM; Kramer BS; Crawford ED
    Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconsidering the Trade-offs of Prostate Cancer Screening.
    Shoag JE; Nyame YA; Gulati R; Etzioni R; Hu JC
    N Engl J Med; 2020 Jun; 382(25):2465-2468. PubMed ID: 32558473
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer remains controversial.
    Stark JR; Mucci L; Rothman KJ; Adami HO
    BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
    [No Abstract]   [Full Text] [Related]  

  • 11. The Melbourne Consensus Statement on the early detection of prostate cancer.
    Murphy DG; Ahlering T; Catalona WJ; Crowe H; Crowe J; Clarke N; Cooperberg M; Gillatt D; Gleave M; Loeb S; Roobol M; Sartor O; Pickles T; Wootten A; Walsh PC; Costello AJ
    BJU Int; 2014 Feb; 113(2):186-8. PubMed ID: 24206066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing prostate cancer overdiagnosis from becoming overtreatment.
    Hayes J; Barry MJ
    Oncology (Williston Park); 2011 May; 25(6):468, 471, 478. PubMed ID: 21717900
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
    Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
    Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: PSA update--no change yet.
    Phillips R
    Nat Rev Urol; 2014 Sep; 11(9):483. PubMed ID: 25134834
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    Pinsky PF; Prorok PC; Kramer BS
    N Engl J Med; 2017 Mar; 376(13):1285-1289. PubMed ID: 28355509
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate-specific antigen-based prostate cancer screening: Past and future.
    Alberts AR; Schoots IG; Roobol MJ
    Int J Urol; 2015 Jun; 22(6):524-32. PubMed ID: 25847604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer: time to put all the data on the table.
    Haines IE; Ablin RJ; Miklos GL
    BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
    [No Abstract]   [Full Text] [Related]  

  • 20. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.